According to a new market report published by Lucintel, the future of the liquid biopsy market looks promising with opportunities in the reference laboratories, hospitals, physician laboratories, and academic and research centers end use segments. The liquid biopsy market is expected to grow with a CAGR of 23% from 2019 to 2024. The major drivers for this market are increasing prevalence of cancer, increasing preference for noninvasive procedures, rising emphasis on personalized medicine, and availability of funding for liquid biopsy research and development.
To download report brochure, please go to https://www.lucintel.com/liquid-biopsy-market.aspx and click "report brochure" tab
Liquid biopsy tests are executed to understand the molecular aspects of early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring orthopedics applications. Therapy selection is the largest application segment of the liquid biopsy market.
North America will remain the largest region over the forecast period due to recent regulatory approvals by CE for commercial use of these liquid biopsy tests.
Biocept, Qiagen N.V., Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini-Silicon Biosystems, Trovagene, Guardant Health, Mdxhealth, Genomic Health, Raindance Technologies, Thermo Fisher Scientific, and Illumina are among the major players of liquid biopsy.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the liquid biopsy market by product, circulating biomarker, clinical application, application, end use, and region. Lucintel has prepared a comprehensive research report titled "Liquid Biopsy Market 2019-2024: Trends, Forecast, and Opportunity Analysis". The Lucintel report serves as a catalyst for growth strategy as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes a forecast for the liquid biopsy market by product, circulating biomarker, clinical application, application, end use, and region as follows:
By Product [$M shipment analysis for 2013 – 2024]:
Assays Kits
Instruments
Services
By Circulating Biomarker [$M shipment analysis for 2013 – 2024]:
Circulating Tumor Cells (CTCs)
Circulating Tumor DNA (ctDNA)
Cell-Free DNA (cfDNA)
Extracellular Vesicles (EVs)
Other Circulating Biomarkers
By Clinical Application [$M shipment analysis for 2013 – 2024]:
Therapy Selection
Treatment Monitoring
Recurrence Monitoring Orthopedics
By Application [$M shipment analysis for 2013 – 2024]:
Oncology
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Other Cancers
Non-Cancer
By End Use [$M shipment analysis for 2013 – 2024]:
Reference Laboratories
Hospitals and Physician Laboratories
Academic and Research Centers
Other End Users
By Region [$M shipment analysis for 2013 – 2024]:
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Asia-Pacific
ROW
This 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link https://www.lucintel.com/liquid-biopsy-market.aspx or helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.